Start here: the honest default
No treatment is approved for long COVID. This is a supportive bundle aimed at symptoms, so its modest claims and weak evidence come first, before any sense that it is a fix.
It is also tied to a contested diagnosis. The mast cell label is frequently over-applied, so before committing to a treatment built around it, it is worth being confident the underlying picture is genuinely mast-cell driven.
What is in the bundle
The bundle combines the plant flavonoids quercetin and luteolin, the prescription asthma drug montelukast, and a low-histamine diet, all meant to settle mast cell activity from different angles. None of these is a long COVID treatment in its own right; they are borrowed for their calming effect on mast cells.
The support is graded low and thin, based on how people say they feel rather than on controlled trials.1
lowthin evidencesupportive, not curative
What the evidence shows, and what it costs
There is no controlled trial showing the bundle changes the course of long COVID. What exists is patient-reported relief, which is real to the people experiencing it but cannot separate the treatment from natural fluctuation.
The costs are not trivial. A low-histamine diet is restrictive and can quietly narrow your nutrition if followed without guidance, and montelukast is a prescription with its own cautions, including mood effects. The flavonoids are generally low-risk but not free of interactions.
What each piece is trying to do
The bundle attacks mast cell activation from several directions at once, which is part of why it appeals and part of why it is hard to evaluate. Quercetin and luteolin are plant flavonoids studied for a mast-cell-stabilizing effect, montelukast is a prescription drug that blocks one of the inflammatory signals mast cells use, and a low-histamine diet aims to lower the overall load the system has to cope with.
Stacked together they are meant to calm an overactive response from membrane to mediator to diet. Individually, none of them is a long COVID treatment in its own right; each is borrowed for its calming effect on mast cells. The combined evidence for the stack remains patient-reported rather than trial-grade, which is real to the people who feel better on it but cannot, by its nature, separate the treatment from natural fluctuation in symptoms.
The diet's hidden cost
The low-histamine diet deserves singling out, because it is the component most capable of doing harm. Followed strictly and without guidance, it can quietly narrow your nutrition, make eating socially and practically difficult, and add a layer of daily stress, all in pursuit of a benefit that remains uncertain. A diet that costs you nutrition and quality of life is not a neutral experiment, even when it is framed as a gentle, natural option.
If you try it, doing so with dietary support and a clear time limit protects you from drifting into long-term over-restriction that outlasts any benefit. Build in the gentlest pieces first, keep a simple symptom diary so you can actually tell whether anything is helping, and be willing to stop a component that is clearly doing nothing after a fair trial. Treat the whole approach as a symptom experiment, not a cure, and the restrictive diet as the part most in need of guardrails.
When the diagnosis underneath is shaky
There is a deeper caution specific to this bundle. Because it is built around a mast cell diagnosis, and because that label is so often applied from a symptom checklist rather than strict criteria, it is possible to commit to a demanding regimen aimed at a problem you may not actually have in the strict sense. That is a lot of effort and restriction resting on an uncertain foundation.
So before building a long-term regimen on it, it is worth revisiting how the underlying diagnosis was made. If it rested on a checklist alone, the honest move is to ask whether you meet the criteria-based definition, mediators and treatment response included. Your symptoms are real and worth addressing whatever they are called, but a supportive, weak-evidence bundle is most justified when the picture genuinely points at mast cells rather than when the label was reached for in the absence of a better one.
What to weigh
If these measures ease your symptoms, that is a reasonable reason to use them, as long as you treat them as supportive rather than disease-modifying. Be especially careful with the diet, which is the part most likely to cause harm through over-restriction for little gain.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether any single component does the work, or whether none of them does.
- Who, if anyone, responds reliably, as opposed to improving on their own.
- How long to try the bundle before concluding it is not helping.
- Whether reported benefit reflects mast cells or something else entirely.
- Whether the low-histamine diet's risks outweigh its modest symptom relief.
- How this approach interacts with the overdiagnosis problem around the mast cell label itself.
What this means for you
If you want to try this bundle, the lowest-risk way in is to start with the gentlest pieces, keep a simple symptom diary, and get dietary guidance before committing to a restrictive low-histamine plan. Treat it as a symptom experiment, not a cure.
If a component is clearly not helping after a fair trial, it is reasonable to stop it. And if the whole approach rests on a mast cell diagnosis you were given from a checklist rather than strict criteria, that diagnosis is worth revisiting before you build a long-term regimen on it.
References
Each reference links to the source on PubMed, PMC, or the publisher.